1-Benzyl-3-(5-{[(2,4-dichlorophenyl)methyl]sulfanyl}-1,3,4-oxadiazol-2-yl)-1,2-dihydropyridin-2-one

Catalog No. :
ACLBWF817
CAS No. :
242472-23-7
Molecular Formula :
C21H15Cl2N3O2S
Molecular Weight :
444.34

IUPAC Name:1-benzyl-3-(5-((2,4-dichlorobenzyl)thio)-1,3,4-oxadiazol-2-yl)pyridin-2(1H)-one

1-Benzyl-3-(5-{[(2,4-dichlorophenyl)methyl]sulfanyl}-1,3,4-oxadiazol-2-yl)-1,2-dihydropyridin-2-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g90%$296.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Benzyl-3-(5-{[(2,4-dichlorophenyl)methyl]sulfanyl}-1,3,4-oxadiazol-2-yl)-1,2-dihydropyridin-2-one
IUPAC Name1-benzyl-3-(5-((2,4-dichlorobenzyl)thio)-1,3,4-oxadiazol-2-yl)pyridin-2(1H)-one
MDL No.MFCD00140477
Molecular FormulaC21H15Cl2N3O2S
Molecular Weight444.34
SMILESO=C1C(C2=NN=C(SCC3=CC=C(Cl)C=C3Cl)O2)=CC=CN1CC4=CC=CC=C4
InChI KeyZMBWTJAFAWUOTG-UHFFFAOYSA-N
Synonym1-BENZYL-3-(5-[(2,4-DICHLOROBENZYL)SULFANYL]-1,3,4-OXADIAZOL-2-YL)-2(1H)-PYRIDINONE;1-benzyl-3-(5-{[(2,4-dichlorophenyl)methyl]sulfanyl}-1,3,4-oxadiazol-2-yl)-1,2-dihydropyridin-2-one;2(1H)-Pyridinone, 3-[5-[[(2,4-dichlorophenyl)methyl]thio]-1,3,4-oxadiazol-2-yl]-1-(phenylmethyl)-
CAS No.242472-23-7

Synthetic Route by SureRoute

1. ACLBWF817 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACOWGM620 route compound structure diagram
    ACOWGM62020443-99-6 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLBWF817 route product structure diagram
    ACLBWF817242472-23-7
Inquiry

2. ACLBWF817 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACLBWF817 route product structure diagram
    ACLBWF817242472-23-7
Inquiry

Comments (0)